Bissonnette R, et al. - Authors evaluated the effectiveness and safety of secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, through 5 years of treatment in moderate-to-severe psoriasis. In patients with moderate-to-severe psoriasis, high and sustained levels of skin clearance and improved quality of life through 5 years was delivered with secukinumab 300 mg treatment. In the secukinumab phase 2/3 programme, favourable safety established was maintained through 5 years. Approximately 90% average improvement in mean Psoriasis Area and Severity Index (PASI) was seen through 5 years vs core study baseline.